AVROBIO (Nasdaq:AVRO) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVRO Stoklara Genel Bakış

A clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States.

Şirket hakkında

AVRO temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Fiyat-Kazanç oranı ( 24.9 x) Biotechs endüstri ortalamasının ( 18.6 x) altındadır

Bu yıl karlı hale geldi

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 18.4% oranında düşmesi öngörülüyor

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Anlamlı bir piyasa değeri yok ( $64M )

AVROBIO, Inc. Rakipler

Spero Therapeutics

NasdaqGS:SPRO

US$66.5m

Eagle Pharmaceuticals

OTCPK:EGRX

US$5.2m

Protalix BioTherapeutics

NYSEAM:PLX

US$86.0m

CytomX Therapeutics

NasdaqGS:CTMX

US$77.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti AVROBIO
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$16.80
52 Haftanın En Yüksek Seviyesi	US$19.80
52 Haftanın En Düşük Seviyesi	US$10.56
Beta	1.22
11 Aylık Değişim	1.45%
3 Aylık Değişim	9.38%
1 Yıllık Değişim	44.82%
33 Yıllık Değişim	-85.45%
5 Yıllık Değişim	-90.89%
Halka arzdan bu yana değişim	-95.51%

Son Haberler & Güncellemeler

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Hissedar Getirileri

	AVRO	US Biotechs	US Pazar
7D	-4.8%	0.5%	0.5%
1Y	44.8%	24.7%	36.8%

Getiri vs. Endüstri: AVRO geçen yıl % 24.7 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: AVRO geçen yıl % 36.8 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: AVRO son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: AVRO 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc. Temel Bilgiler Özeti

AVROBIO'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AVRO temel i̇stati̇sti̇kler
Piyasa değeri	US$63.75m
Kazançlar(TTM)	US$30.31m
Gelir(TTM)	n/a

24.9x

F/K Oranı

0.0x

P/S Oranı

AVRO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AVRO gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	-US$30.31m
Kazançlar	US$30.31m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.68
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

AVRO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company is no longer active

AVRO Stoklara Genel Bakış

Ödüller

Risk Analizi

AVROBIO, Inc. Rakipler

NasdaqGS:SPRO

US$66.5m

OTCPK:EGRX

US$5.2m

NYSEAM:PLX

US$86.0m

NasdaqGS:CTMX

US$77.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline